Processa Pharmaceuticals, Inc. (PCSA)

Processa Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-9.83	-11.12	-27.42	-11.43	-14.41	-3.36
Depreciation & Amortization	0.08	0.08	0.87	0.88	0.88	0.88
Share-Based Compensation	0.89	1.06	8.83	3.41	2.73	0.51
Other Operating Activities	0.86	1.92	8.12	-1.57	7.66	-0.78
Operating Cash Flow	-8	-8.06	-9.61	-8.72	-3.14	-2.75
Capital Expenditures	0	-0	0	0	0	0
Investing Cash Flow	0	-0	0	0	0	0
Share Issuance / Repurchase	6.19	6.27	-0.3	10.05	17.1	0.9
Debt Issued / Paid	-0	0	0	0	0.86	0.8
Other Financing Activities	-0.01	-	-0.09	-0.25	-0.1	-
Financing Cash Flow	6.18	6.27	-0.39	9.8	17.87	1.7
Net Cash Flow	-1.82	-1.8	-9.99	1.08	14.72	-1.05
Free Cash Flow	-8	-8.07	-9.61	-8.72	-3.14	-2.75
Free Cash Flow Per Share	-3.24	-6.15	-11.93	-11.38	-8.38	-9.95

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).